Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT04849364 · Bryan Schneider, MD · PHASE2 · terminated · last registry update 2025-05-31 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funder Decision” | – | Registry record, Bryan Schneider, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PARP2 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-29Results posted on the registry: Memorial Sloan Kettering Cancer Center, Olaparib + Pembrolizumab (NCT05203445)
- 2026-04-08Results posted on the registry: National Cancer Institute (NCI), Cisplatin + Veliparib (NCT02595905)
- 2026-03-20Phase 3 first posted: The Netherlands Cancer Institute, Standard of care plus pembrolizumab + Standard of care (capecitabine or olaparib) (NCT07486687)
- 2026-02-25Also stopped (terminated): Gordon Mills, MD, PhD, Capivasertib + Ceralasertib (NCT03801369)
- 2026-02-19Also stopped (withdrawn): Merck Sharp & Dohme LLC, Pembrolizumab + Paclitaxel (NCT06829199)
- 2026-01-22Results posted on the registry: University of Alabama at Birmingham, Combination of Veliparib + Lapatinib (NCT02158507)
- 2025-12-22Also stopped (terminated): Thomas Jefferson University, Olaparib (NCT03955640)
- 2025-12-08Results posted on the registry: Memorial Sloan Kettering Cancer Center, Rucaparib (NCT03542175)
- 2025-11-21Results posted on the registry: Rush University Medical Center, Folic Acid Tablet (NCT04024254)
- 2025-11-21Results posted on the registry: Gordon Mills, MD, PhD, Capivasertib + Ceralasertib (NCT03801369)
- 2025-10-07Results posted on the registry: Zenith Epigenetics, ZEN003694 + Talazoparib (NCT03901469)
- 2025-10-07Also stopped (terminated): Zenith Epigenetics, ZEN003694 + Talazoparib (NCT03901469)
- 2025-09-17Phase 3 first posted: Women's Cancer Study Group GmbH, Sacituzumab govitecan + Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA] (NCT07178730)
- 2025-08-17Also stopped (withdrawn): Stanford University, Talazoparib Tosylate (NCT04756765)
- 2025-08-15Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Veliparib (NCT01149083)
- 2025-05-29Results posted on the registry: Yuan Yuan, Pembrolizumab + Olaparib (NCT03025035)
- 2025-05-13Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06966700)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision